论文部分内容阅读
高眼压症的治疗仍是一个高度争论的课题。在世界文献中高眼压症开始治疗的标准很不一样。有下列三方面作为衡量决策的考虑: 一、什么是病人发生视野损害的危险。二、什么是预防这些情况的有效治疗。三、哪些问题使治疗必需。估计造成损害率的情况有助于决定采用的措施。我们研究的对象是70例经完全的青光眼险查后确诊为高眼压症者。很多危险因素,如年龄,青光眼家族史,糖尿病,心血管病,甲状腺病等都是有助于评价是否应开始治疗的。治疗方法的选择是受一些情况支配的: 毛果芸香硷在很多病人是首选的药物。年青人和有中央性白内障改变的病人选择左旋肾上腺素。对毛果芸香硷和左旋肾上腺素疗效差者可选用噻吗心安。罕用全身药物治疗,只有一例用手术治疗。作者将讨论有高眼压症的病人是否要接受防止青光眼性视野损害的治疗,同时详细综述治疗的方法和可能遇到的问题。
Treatment of ocular hypertension is still a highly controversial issue. In the world literature, the standard of treatment for ocular hypertension is very different. There are three aspects as a measure of decision-making considerations: First, what is the danger of patient vision damage. Second, what is the effective prevention of these conditions? Third, what issues make the treatment necessary. It is estimated that the circumstances that led to the damage rate will help to decide on the measures to be adopted. The subjects we studied were 70 patients diagnosed with ocular hypertension after a complete glaucoma investigation. Many risk factors, such as age, family history of glaucoma, diabetes, cardiovascular disease, thyroid disease, are all helpful in evaluating whether treatment should be initiated. The choice of treatment is governed by some conditions: pilocarpine is the drug of choice in many patients. L-epinephrine is selected among young people and patients with central cataract changes. Psoriasis and L-epinephrine poor efficacy may choose timolol. Rare systemic drug treatment, only one case with surgery. The authors discuss whether patients with ocular hypertension should receive treatment to prevent glaucomatous visual field damage and at the same time provide a detailed review of treatment methods and possible problems.